One company’s stock is grossly underrated these days, as are many small-cap biotechs. Market psychology often disguises the long-term value of a company.

In my opinion,there is no company that has a bigger platform and a more undervalued stock…

The platform is nonembryonic human parthenogenetic (often shortened to “parthenogenic”) stem cells (hpSCs). The company in question developed a way to make pluripotent stem cells using unused oocytes (immature unfertilized ova or eggs) gathered in the process of in vitro fertilization.

As a result, it owns the intellectual property on these remarkable cells.

There a number of advantages inherent in these hpSCs. One is that those who are opposed to the use of embryonic cells in therapies need not worry.

Cells made from these lines could be manufactured and kept ready for use at any time. Once you have determined your cell type, like your blood types, you could buy specific stem cells “off the shelf” for whatever purpose you have. And, in most cases, the differentiated hpSCs could be used with little or no immune suppression.

Some people believe that the actual number of hpSC lines needed to treat 85% of all humans is as few as ten. The company is in the process right now of finding the right oocyte donors and creating those hpSC lines.

Currently, the company is moving ahead in four principal areas: retinal, corneal, liver and neural cells. The eye tissues will, I suspect, come to market first. There are tens of millions of people in Asia whose sight could be restored if they had access to transplant eye tissues. Because the infrastructure for organ donations does not exist, however, Asian scientists are enormously excited about bringing hpSC retinal and corneal tissues to their populations.

While growing parthenogenic corneal stem cells for research purposes, beautiful sphere or orbs of human eye tissue formed spontaneously, pointing to the power of these stem cells.

Though no one had set out to produce artificial eyes for the purpose of product testing, it was an obvious possibility. Draize testing is a method for testing chemicals used in all kinds of products, from cosmetics and cleaning supplies to drugs and perfumes, for human safety. The actual procedure involves applying the chemicals to living animals’ eyes. Then, the eyes are often removed for testing.

Tests performed indicate that the hpSCs perform as well as, if not better than, animal eyes as a predictor for toxicity. This isn’t surprising, as the orbs are living human cells.

Needless to say, this is an important milestone, as Draize testing is currently a multibillion-dollar industry and everyone would like to see the procedure minimized. If animal lovers realize that there is now an alternative, I think the pressure to buy corneal orbs will be significant…

Yours for transformational profits,

Patrick Cox
for The Penny Sleuth

Related Posts

• September 22, 2011 -- The UN Wants You to Consume Less Food and Exercise
• March 11, 2009 -- Breaking Stem Cell News on Immunosuppression
• September 18, 2009 -- This Company’s Failure Clears Your Path to Real Stem Cell Fortunes
• August 4, 2010 -- The Startup That Could Build You New Organs — And Make Its Investors Rich
• March 19, 2009 -- How Transformational Biotech Will Make You Richer Than Early Computer Investors

Patrick Cox

Patrick Cox has lived deep inside the world of transformative technologies for over 25 years. In the 1980s, he worked in computer software development and manufacturing. By the mid-1990s, he worked as a consultant for Netscape — the company that handled 90% of all Internet browsing traffic at the time. InfoWorld and USA Today have featured Patrick's research numerous times. He's also appeared on Crossfire and Nightline. Patrick has been quoted by The Wall Street Journal and Reason magazine. His expertise brought him to Agora Financial, where he now heads Breakthrough Technology Alert, the only place you'll find the truly transformational technologies that offer exponential gains.

View articles by Patrick Cox